Interleukin 10 has been shown to exert an inhibitory role over T-lymphocyte reactions and as such has been suggested as a potential inhibitory molecule affecting tumour infiltrating lymphocytes (TIL) in the breast cancer microenvironment. This evidence concerns the gene IL10 and breast carcinoma.